Coronavirus Disease 2019 (COVID-19) Severity Among Women of Reproductive Age With Symptomatic Laboratory-Confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection by Pregnancy Status-United States, 1 January 2020-25 December 2021

被引:19
|
作者
Strid, Penelope [1 ]
Zapata, Lauren B. [1 ]
Tong, Van T. [1 ]
Zambrano, Laura D. [1 ]
Woodworth, Kate R. [1 ]
Riser, Aspen P. [1 ]
Galang, Romeo R. [1 ]
Gilboa, Suzanne M. [1 ]
Ellington, Sascha R. [1 ]
机构
[1] Ctr Dis Control & Prevent, Epidemiol Task Force, Pregnancy & Infant Linked Outcomes Team, COVID 19 Emergency Response, Atlanta, GA 30341 USA
关键词
pregnancy; COVID-19; SARS-CoV-2; Delta variant; women of reproductive age; VACCINATION;
D O I
10.1093/cid/ciac479
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Information on the severity of coronavirus disease 2019 (COVID-19) attributable to the Delta variant in the United States among pregnant people is limited. We assessed the risk for severe COVID-19 by pregnancy status in the period of Delta variant predominance compared with the pre-Delta period. Methods. Laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections among symptomatic women of reproductive age (WRA) were assessed. We calculated adjusted risk ratios for severe disease including intensive care unit (ICU) admission, receipt of invasive ventilation or extracorporeal membrane oxygenation (ECMO), and death comparing the pre-Delta period (1 January 2020-26 June 2021) and the Delta period (27 June 2021-25 December 2021) for pregnant and nonpregnant WRA. Results. Compared with the pre-Delta period, the risk of ICU admission during the Delta period was 41% higher (adjusted risk ratio [aRR], 1.41 [95% confidence interval {CI}, 1.17-1.69]) for pregnant WRA and 9% higher (aRR, 1.09 [95% CI, 1.00-1.18]) for nonpregnant WRA. The risk of invasive ventilation or ECMO was higher for pregnant (aRR, 1.83 [95% CI, 1.26-2.65]) and nonpregnant (aRR, 1.34 [95% CI, 1.17-1.54]) WRA in the Delta period. During the Delta period, the risk of death was 3.33 (95% CI, 2.48-4.46) times the risk in the pre-Delta period among pregnant WRA and 1.62 (95% CI, 1.49-1.77) among nonpregnant WRA. Conclusions. Compared with the pre-Delta period, pregnant and nonpregnant WRA were at increased risk for severe COVID-19 in the Delta period.
引用
收藏
页码:S317 / S325
页数:9
相关论文
共 50 条
  • [31] Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load in the Upper Respiratory Tract of Children and Adults With Early Acute Coronavirus Disease 2019 (COVID-19)
    Baggio, Stephanie
    L'Huillier, Arnaud G.
    Yerly, Sabine
    Bellon, Mathilde
    Wagner, Noemie
    Rohr, Marie
    Huttner, Angela
    Blanchard-Rohner, Geraldine
    Loevy, Natasha
    Kaiser, Laurent
    Jacquerioz, Frederique
    Eckerle, Isabella
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (01) : 148 - 150
  • [32] Utility of Follow-up Coronavirus Disease 2019 (COVID-19) Antigen Tests After Acute Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Healthcare Personnel
    Tande, Aaron J.
    Swift, Melanie D.
    Challener, Douglas W.
    Berbari, Elie F.
    Tommaso, Christopher P.
    Christopherson, Darrin R.
    Binnicker, Matthew J.
    Breeher, Laura E.
    CLINICAL INFECTIOUS DISEASES, 2022, 75 (01) : E347 - E349
  • [33] Age-Related Differences in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Levels in Patients With Mild to Moderate Coronavirus Disease 2019 (COVID-19)
    Heald-Sargent, Taylor
    Muller, William J.
    Zheng, Xiaotian
    Rippe, Jason
    Patel, Ami B.
    Kociolek, Larry K.
    JAMA PEDIATRICS, 2020, 174 (09) : 902 - 903
  • [34] Does Chronic Treatment with Oral Anticoagulants Ameliorate the Clinical Course of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Coronavirus Disease 2019 (COVID-19)?
    Harenberg, Job
    Bauersachs, Rupert
    Ageno, Walter
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2021, 47 (04): : 338 - 340
  • [35] Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel
    Swift, Melanie D.
    Breeher, Laura E.
    Tande, Aaron J.
    Tommaso, Christopher P.
    Hainy, Caitlin M.
    Chu, Haitao
    Murad, M. Hassan
    Berbari, Elie F.
    Virk, Abinash
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (06) : E1376 - E1379
  • [36] Impact of Convalescent Plasma Therapy on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Profile in Coronavirus Disease 2019 (COVID-19) Patients
    Tang, Juanjie
    Grubbs, Gabrielle
    Lee, Youri
    Golding, Hana
    Khurana, Surender
    CLINICAL INFECTIOUS DISEASES, 2022, 74 (02) : 327 - 334
  • [37] Risk factors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA environmental contamination in rooms of patients with coronavirus disease 2019 (COVID-19)
    Seo, Jun-Won
    Kim, Da Young
    Yun, Na Ra
    Lee, You Mi
    Panchali, Merlin Jayalal Lawrence
    Bang, Mi-Seon
    Hwang, Seong Yeon
    Kim, Choon-Mee
    Kim, Dong-Min
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2023, 44 (05): : 827 - 829
  • [38] Persistent Coronavirus Disease 2019 (COVID-19) in an Immunocompromised Host Treated by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific Monoclonal Antibodies
    Bailly, Benoit
    Pere, Helene
    Veyer, David
    Berceanu, Ana
    Daguindau, Etienne
    Roux, Pauline
    Hermine, Olivier
    de Lamballerie, Xavier
    Bastard, Paul
    Lacombe, Karine
    Autran, Brigitte
    Delettre, Fanny Angelot
    Casanova, Jean Laurent
    Imbeaud, Sandrine
    Laure Clairet, Anne
    Kroemer, Marie
    Spehner, Laurie
    Robillard, Nicolas
    Puech, Julien
    Marty-Quinternet, Solene
    Lepiller, Quentin
    Chirouze, Catherine
    Bouiller, Kevin
    CLINICAL INFECTIOUS DISEASES, 2022, 74 (09) : 1706 - 1707
  • [39] Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination and Booster on Coronavirus Disease 2019 (COVID-19) Symptom Severity Over Time in the COVID-OUT Trial
    Boulware, David R.
    Murray, Thomas A.
    Proper, Jennifer L.
    Tignanelli, Christopher J.
    Buse, John B.
    Liebovitz, David M.
    Nicklas, Jacinda M.
    Cohen, Kenneth
    Puskarich, Michael A.
    Belani, Hrishikesh K.
    Siegel, Lianne K.
    Klatt, Nichole R.
    Odde, David J.
    Karger, Amy B.
    Ingraham, Nicholas E.
    Hartman, Katrina M.
    Rao, Via
    Hagen, Aubrey A.
    Patel, Barkha
    Fenno, Sarah L.
    Avula, Nandini
    Reddy, Neha, V
    Erickson, Spencer M.
    Lindberg, Sarah
    Fricton, Regina
    Lee, Samuel
    Zaman, Adnin
    Saveraid, Hanna G.
    Tordsen, Walker J.
    Pullen, Matthew F.
    Sherwood, Nancy E.
    Huling, Jared D.
    Bramante, Carolyn T.
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (03) : E1 - E9
  • [40] Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific T Cells and Antibodies in Coronavirus Disease 2019 (COVID-19) Protection: A Prospective Study
    Molodtsov, Ivan A.
    Kegeles, Evgenii
    Mitin, Alexander N.
    Mityaeva, Olga
    Musatova, Oksana E.
    Panova, Anna E.
    Pashenkov, Mikhail, V
    Peshkova, Iuliia O.
    Alsalloum, Almaqdad
    Asaad, Walaa
    Budikhina, Anna S.
    Deryabin, Alexander S.
    Dolzhikova, Inna, V
    Filimonova, Ioanna N.
    Gracheva, Alexandra N.
    Ivanova, Oxana I.
    Kizilova, Anastasia
    Komogorova, Viktoria V.
    Komova, Anastasia
    Kompantseva, Natalia, I
    Kucheryavykh, Ekaterina
    Lagutkin, Denis A.
    Lomakin, Yakov A.
    Maleeva, Alexandra, V
    Maryukhnich, Elena, V
    Mohammad, Afraa
    Murugin, Vladimir V.
    Murugina, Nina E.
    Navoikova, Anna
    Nikonova, Margarita F.
    Ovchinnikova, Leyla A.
    Panarina, Yana
    Pinegina, Natalia, V
    Potashnikova, Daria M.
    Romanova, Elizaveta, V
    Saidova, Aleena A.
    Sakr, Nawar
    Samoilova, Anastasia G.
    Serdyuk, Yana
    Shakirova, Naina T.
    Sharova, Nina, I
    Sheetikov, Saveliy A.
    Shemetova, Anastasia F.
    Shevkova, Liudmila, V
    Shpektor, Alexander, V
    Trufanova, Anna
    Tvorogova, Anna, V
    Ukrainskaya, Valeria M.
    Vinokurov, Anatoliy S.
    Vorobyeva, Daria A.
    CLINICAL INFECTIOUS DISEASES, 2022, 75 (01) : E1 - E9